ATX-04 Pompe program advanced with a Duke license signed in February 2026; IV tramadol Phase 3 safety study remains subject to financing or partnership.
Quarterly results
Avenue Therapeutics posted a net loss of USD 690,000 for the quarter ended June 30, 2026, swinging from net income of USD 329,000 a year earlier.
No revenue was recorded, versus USD 1.4 million in other revenue in the prior-year quarter tied to the AnnJi license termination and program transfer.
Total operating expenses fell 36% to USD 707,000, driven by a 50% drop in general and administrative costs to USD 460,000.
Operating loss widened to USD 707,000 from operating income of USD 297,000, while interest income slipped 45% to USD 17,000.
ATXI•
